Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A study in healthy people to compare how 2 different high dose formulations of BI 1015550 are taken up in the body
Boehringer Ingelheim
Pharmacokinetic trial
1 trial -
A study in healthy people to compare how 2 different low dose formulations of BI 1015550 are taken up in the body
Boehringer Ingelheim
Pharmacokinetic trial
1 trial -
A study in healthy people to compare how 3 different formulations of survodutide are taken up in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to compare two different Sifrol® tablets
Boehringer Ingelheim
Pharmacokinetic trial
1 trial -
A study in healthy people to compare two different tablets of BI 685509 and to test how food and esomeprazole influence the amount of BI 685509 in the blood
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to compare two tablet formulations of pramipexole
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to see how zongertinib is taken up into the blood when given as tablets made by two different manufacturers
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how 2 different doses of BI 1291583 are taken up in the body when given in 3 different formulations.
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how 2 different formulations of BI 690517 are taken up in the body and how probenecid influences the amount of BI 690517 in the blood
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how 3 different formulations of BI 764198 are taken up in the body and how this is influenced by food
Boehringer Ingelheim
healthy volunteer trial
1 trial -
A study in healthy people to test how BI 1015550 is taken up in the body when given with or without food
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how empagliflozin is taken up in the body when taken as a whole tablet or dissolved in water and mixed with food
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how itraconazole influences the amount of BI 3031185 in the blood
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how vicadrostat affects the heart
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test how well different doses of BI 3000202 are tolerated and how they affect the way the body handles midazolam
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test whether BI 1291583 influences the amount of dabigatran in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test whether BI 3000202 affects how 2 other medicines (rosuvastatin and digoxin) are taken up in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test whether BI 764198 influences the amount of metformin in the body
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in healthy people to test whether erythromycin influences the amount of BI 1291583 in the blood.
Boehringer Ingelheim
Healthy volunteer trial
1 trial -
A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)
Boehringer Ingelheim
advanced solid tumors
1 trial -
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps
Boehringer Ingelheim
Melanoma, Solid tumours
1 trial -
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab
Boehringer Ingelheim
unresectable advanced or metastatic solid cancer
1 trial -
A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor
Boehringer Ingelheim
Solid cancer tumors
1 trial -
A study in people with obesity to test the effects of different doses of BI 456906 compared with semaglutide on glucagon receptor activity in the liver
Boehringer Ingelheim
No targeted indication. Male and female subjects with obesity.
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources